Sugi Predict

Sugi Predict / Compounds / SCHEMBL6465602

SCHEMBL6465602

SCHEMBL6465602

Clc1cccc2nccc(Cl)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.50
▸ CYP1A2 P05177 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ NR4A2 P43354 1/20 0.39
▸ AURKA O14965 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ CYP2A6 P11509 1/20 0.36
▸ GRIN1 Q05586 2/20 0.36
▸ GRIN2A Q12879 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29404834 1.00 PARP1 (0.50) PARP1CYP1A2ALDH1A1CYP2C9HPGD
SCHEMBL7461243 0.83 PARP1 (0.44) PARP1CYP1A2ALDH1A1CYP2C9HPGD
SCHEMBL20444679 0.83 PDPK1 (0.47) PARP1CYP1A2ALDH1A1CYP2C9HPGD
SCHEMBL4620129 0.83 PARP1 (0.44) PARP1CYP1A2ALDH1A1CYP2C9HPGD
SCHEMBL8603889 0.83 PARP1 (0.44) PARP1CYP1A2ALDH1A1CYP2C9HPGD
SCHEMBL2221871 0.83 PDPK1 (0.52) PARP1CYP1A2ALDH1A1CYP2C9HPGD
SCHEMBL15139040 0.83 NR4A2 (0.52) PARP1CYP1A2ALDH1A1CYP2C9HPGD
SCHEMBL9984695 0.83 PARP1 (0.44) PARP1CYP1A2ALDH1A1CYP2C9HPGD
SCHEMBL21101484 0.83 PARP1 (0.44) PARP1CYP1A2ALDH1A1CYP2C9HPGD
SCHEMBL23479216 0.78 PARP1 (0.41) PARP1CYP1A2ALDH1A1CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111675653-A Preparation method and application of impurities of 4-aminoquinoline compound 珠海润都制药股份有限公司 2020-09-18 — — CN claimed
CN-109928925-A The sublimation purification method of one kind 4,7- dichloroquinoline 重庆康乐制药有限公司 2019-06-25 — — CN claimed
EP-4511114-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 — — EP disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
EP-4322954-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2024-02-21 — — EP disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
US-20030105129-A1 Chemical compounds ASTRAZENECA AB (SE) 2003-06-05 — — US disclosed
EP-1294709-A2 QUINOLINE DERIVATIVES AND THEIR USE AS AURORA 2 KINASE INHIBITORS AstraZeneca AB (SE) 2003-03-26 — — EP disclosed
EP-0326330-B1 Quinoline fungicides DOW AGROSCIENCES LLC (US) 2002-07-24 — — EP disclosed
WO-2001055116-A2 QUINOLINE DERIVATIVES AND THEIR USE AS AURORA 2 KINASE INHIBITORS ASTRAZENECA AB (SE) 2001-08-02 — — WO disclosed
US-5296484-A Applying fungicide to locus of plant pathogen DOWELANCO (US) 1994-03-22 — — US disclosed
US-5240940-A Synergistic nmixture DOWELANCO (US) 1993-08-31 — — US disclosed
US-5145843-A For plants DOWELANCO (US) 1992-09-08 — — US disclosed
EP-0326328-A2 Quinoline, quinazoline, and cinnoline derivatives DowElanco (US) 1989-08-02 — — EP disclosed
EP-0326330-A2 Quinoline, quinazoline, and cinnoline fungicides DowElanco (US) 1989-08-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS PARP1 1374/4885CYP1A2 4576/4885ALDH1A1 2871/4885
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 PARP1 4358/4885CYP1A2 1223/4885ALDH1A1 1762/4885
US-20030105129-A1 Chemical compounds AURKC, AURKA, AURKB PARP1 2150/4885CYP1A2 1333/4885ALDH1A1 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.